Cocrystal Pharma, Inc. (NASDAQ:COCP – Free Report) – Research analysts at Zacks Small Cap raised their FY2025 earnings per share (EPS) estimates for shares of Cocrystal Pharma in a note issued to investors on Tuesday, May 27th. Zacks Small Cap analyst D. Bautz now anticipates that the company will earn ($1.48) per share for the year, up from their previous forecast of ($1.65). The consensus estimate for Cocrystal Pharma’s current full-year earnings is ($1.85) per share.
Cocrystal Pharma (NASDAQ:COCP – Get Free Report) last released its quarterly earnings results on Thursday, May 15th. The company reported ($0.23) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.52) by $0.29.
Cocrystal Pharma Trading Up 9.7%
Cocrystal Pharma Company Profile
Cocrystal Pharma, Inc, a biotechnology company, focuses on the discovery and development of antiviral therapeutic treatments for serious and/or chronic viral diseases. It employs structure-based technologies to create antiviral drugs primarily to treat hepatitis C virus (HCV), influenza virus, coronavirus, norovirus, and respiratory virus infections.
Featured Articles
- Five stocks we like better than Cocrystal Pharma
- How to Start Investing in Real Estate
- Nike’s Amazon Expansion Could Signal a Turnaround in 2025
- How to Use the MarketBeat Stock Screener
- Intel’s Turnaround May Be the Best Bet No One’s Watching
- What Are the U.K. Market Holidays? How to Invest and Trade
- 3 Defense Stocks That Will Profit From a Golden Dome
Receive News & Ratings for Cocrystal Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cocrystal Pharma and related companies with MarketBeat.com's FREE daily email newsletter.